| Name | Title | Contact Details |
|---|
Auxilium is a fully integrated specialty biopharmaceutical company focused on developing and marketing products to predominantly specialist audiences. Auxilium means “assistance” in Latin, and that’s a fitting description for all of our biopharmaceutical development and commercialization efforts. Although we are living in an era of rapid advances in medical technology, many of society’s medical concerns remain unaddressed. Auxilium works to address some of these unmet needs. By doing so, we work in important areas of the pharmaceutical industry that require forward thinking and novel solutions that promote better health and living. Through advancement and expansion, Auxilium is dedicated to providing innovative solutions for underserved diseases that improve health and quality of life.
Columbus Prescription Pharmacies, Inc. is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. We are headquartered in Boston, Massachusetts.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
Venture Healthcare Corporation is a Leesburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.